Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial

By Ben Glickman

Bristol Myers Squibb's said a trial of its drug Zeposia to treat Crohn's disease didn't meet its goals, potentially squashing a new indication for the treatment.

The pharmaceutical giant said on Thursday the trial failed to reach its primary endpoint of clinical remission for moderate to severe active Crohn's disease at week 12, based on an initial analysis. Bristol Myers Squibb said it would complete a full evaluation of the trial data and share results with the scientific community.

Zeposia is approved by regulators for treatment of multiple sclerosis and ulcerative colitis.

Crohn's is a chronic inflammatory bowel disease which affects the digestive tract.

Write to Ben Glickman at ben.glickman@wsj.com